spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Mucopolysaccharidosis 

 HSMN NewsFeed - 31 Mar 2022
Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Sep 2021
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Apr 2020
JCR Pharmaceuticals announces Completion of Acquisition of ArmaGen, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Aug 2018
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2018
Ultragenyx Announces Positive CHMP Opinion for Mepsevii(TM) (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Sep 2017
Eloxx Pharmaceuticals Expands Management Team to Support Rapid Development of Lead Drug Candidate ELX-02 for the Treatment of Rare Genetic Diseases
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 May 2017
Ultragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License Application and Marketing Authorization Application Filed and Accepted for Review; FDA Grants Priority Review Status
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Mar 2017
Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 Genome Editing Treatment for MPS II
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jun 2016
Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Feb 2016
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Apr 2015
ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Jul 2014
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 20 Sep 2013
Vital Therapies, Inc. Expands Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Sep 2013
BioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Sep 2012
BioMarin Names Jeff Ajer Senior Vice President, Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Sep 2010
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Aug 2010
BioMarin Acquires ZyStor Therapeutics, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Apr 2010
BioMarin Launches Firdapse in the European Union
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2010
BioMarin to Acquire LEAD Therapeutics
Biopharmaceuticals Mergers & Acquisitions Oncology
 HSMN NewsFeed - 30 Nov 2009
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Mar 2009
BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Feb 2009
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2009
BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
Biopharmaceuticals
 HSMN NewsFeed - 17 Jul 2008
AMT Appoints Director Global Marketing and Sales
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 May 2008
Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Mar 2008
Naglazyme Approved by Japanese Ministry of Health
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Feb 2008
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jan 2008
BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jan 2008
Steve Glass Appointed Vice President and General Manager, BioMarin Europe, Ltd.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Dec 2007
BioMarin Announces FDA Approval for Kuvan
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Oct 2007
Genzyme Receives Approval to Market Elaprase(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Oct 2007
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Sep 2007
Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Aug 2007
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Biopharmaceuticals
 HSMN NewsFeed - 8 Aug 2007
Paladin Expands Distribution Agreement with Shire HGT to Include ELAPRASE(TM) (Idursulfase)
Biopharmaceuticals Distribution
 HSMN NewsFeed - 25 Jul 2007
Kuvan Receives Priority Review Status from FDA
Biopharmaceuticals
 HSMN NewsFeed - 18 Jun 2007
BioMarin Initiates Expanded Access Program for Kuvan in the U.S.
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2007
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 May 2007
BioMarin Submits New Drug Application for U.S. Marketing Authorization of Kuvan for Phenylketonuria (PKU)
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Dec 2006
BioMarin Announces Positive Results From Phase 3 Extension Study of Phenoptin for PKU
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2006
ELAPRASE(TM) (idursulfase) Receives Positive Opinion in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Aug 2006
BioMarin Announces U.S. Launch of Orapred ODT Through Alliant Pharmaceuticals
Biopharmaceuticals
 HSMN NewsFeed - 24 Jul 2006
Shire's ELAPRASE(TM) (idursulfase) Approved by the Food and Drug Administration (FDA) for Hunter Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jun 2006
BioMarin and Alliant Announce FDA Approval of Orapred ODT
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 15 Mar 2006
BioMarin and Alliant Pharmaceuticals Announce North American Licensing Agreement for Orapred
Biopharmaceuticals Licensing
 HSMN NewsFeed - 15 Mar 2006
BioMarin and Serono Announce Positive Results From Phase 3 Clinical Study of Phenoptin for PKU
Biopharmaceuticals
 HSMN NewsFeed - 30 Jan 2006
BioMarin Receives Marketing Approval for Naglazyme in European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Jan 2006
BioMarin Receives FDA Fast Track Designation for Phenoptin for PKU
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Jan 2006
BioMarin Establishes Commercial Operations in Europe
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 19

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 19 additional stories matching:
Mucopolysaccharidosis
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.